We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$44.5B
AUM Growth
-$1.18B
(-2.6%)
Cap. Flow
-$4.15B
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
9.83%
Holding
3,927
New
652
Increased
690
Reduced
847
Closed
1,056
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$309M |
| 2 |
ExxonMobil
XOM
|
+$302M |
| 3 |
Amazon
AMZN
|
+$291M |
| 4 |
Citigroup
C
|
+$253M |
| 5 |
Shopify
SHOP
|
+$238M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$383M |
| 2 |
Johnson & Johnson
JNJ
|
+$312M |
| 3 |
JPMorgan Chase
JPM
|
+$285M |
| 4 |
AT&T
T
|
+$191M |
| 5 |
Dollar General
DG
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.63% |
| 2 | Financials | 15.61% |
| 3 | Technology | 14.28% |
| 4 | Consumer Discretionary | 13.21% |
| 5 | Industrials | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Aramark
ARMK
$15B
| $29.9M | 0.07% |
1,002,451
+404,808
| +68% | +$11.2M |
|
327
Sociedad Química y Minera de Chile
SQM
$19.6B
| $29.9M | 0.07% |
374,671
+31,675
| +9% | +$2.93M |
|
328
Clearfield
CLFD
$421M
| $29.7M | 0.07% |
315,759
+313,493
| +13,835% | +$33M |
|
329
Celldex Therapeutics
CLDX
$2.77B
| $29.7M | 0.07% |
666,749
+14,028
| +2% | +$501K |
|
330
Comstock Resources
CRK
$3.97B
| $29.3M | 0.07% |
2,138,740
-26,269
| -1% | -$448K |
|
331
Calix
CALX
$2.27B
| $29.1M | 0.07% |
425,856
-62,796
| -13% | -$4.22M |
|
|
332
PUT
ExxonMobil
XOM
$651B
| $29M | 0.07% |
262,600
+108,100
| +70% | +$11.6M |
|
333
Lufax Holding
LU
$1.2B
| $29M | 0.07% |
3,732,502
+584,129
| +19% | +$4.45M |
|
|
GRMN
334
Garmin
GRMN
$46.9B
| $28.9M | 0.07% |
313,576
-68,632
| -18% | -$6.06M |
|
335
Clarivate
CLVT
$1.3B
| $28.9M | 0.07% |
3,464,602
+1,284,389
| +59% | +$12.1M |
|
336
Vale
VALE
$62.9B
| $28.8M | 0.06% |
+1,697,806
| New | +$25.5M |
|
|
EOCW
337
DELISTED
Elliott Opportunity II Corp.
EOCW
| $28.8M | 0.06% |
2,857,509
| – | – |
|
338
Hims & Hers Health
HIMS
$6.5B
| $28.8M | 0.06% |
4,487,038
+2,236,609
| +99% | +$12.7M |
|
339
CALL
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
$45.8B
| $28.6M | 0.06% |
86,200
+43,900
| +104% | +$14.3M |
|
340
T. Rowe Price
TROW
$25B
| $28.5M | 0.06% |
261,413
+257,897
| +7,335% | +$29.2M |
|
341
Abercrombie & Fitch
ANF
$4.17B
| $28.5M | 0.06% |
1,242,070
+507,957
| +69% | +$10M |
|
342
Arista Networks
ANET
$219B
| $28.4M | 0.06% |
935,828
-201,772
| -18% | -$6.21M |
|
343
Lockheed Martin
LMT
$134B
| $28.2M | 0.06% |
57,938
-51,325
| -47% | -$23.8M |
|
344
Synopsys
SNPS
$71.5B
| $28.1M | 0.06% |
88,071
+59,267
| +206% | +$18.6M |
|
|
345
CALL
Amazon
AMZN
$2.5T
| $28.1M | 0.06% |
334,000
+233,100
| +231% | +$23M |
|
346
PUT
State Street SPDR S&P Bank ETF
KBE
$1.64B
| $27.8M | 0.06% |
+616,600
| New | +$28.9M |
|
347
Prologis
PLD
$138B
| $27.8M | 0.06% |
246,833
+185,112
| +300% | +$20.5M |
|
|
P
348
Everpure Inc
P
$24.8B
| $27.8M | 0.06% |
1,038,713
-1,871,007
| -64% | -$54.4M |
|
|
LGAC
349
DELISTED
Lazard Growth Acquisition Corp. I Ordinary Shares
LGAC
| $27.7M | 0.06% |
2,742,530
| – | – |
|
350
Invesco QQQ Trust
QQQ
$455B
| $27.6M | 0.06% |
103,485
+75,850
| +274% | +$21M |
|
Similar funds
Marshall Wace's Q4 2022 Portfolio in Review
As of Q4 2022, Marshall Wace held 3,927 positions worth $44.5B, down 2.6% from $45.6B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Marshall Wace withdrew a net $4.15B in Q4 2022, closing 1,056 positions and reducing 847 holdings. Its most notable exit was Humana, an estimated $383M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Financials and Technology.
Against the trend, Marshall Wace opened a new position in Elevance Health worth $188M.
- Marshall Wace's largest Q4 2022 buy was Elevance Health: 366,649 shares worth $188M.
- Marshall Wace added most to Biogen in Q4 2022, an estimated $309M increase.
- Marshall Wace's biggest Q4 2022 reduction was Johnson & Johnson, cutting an estimated $312M.
- Marshall Wace fully exited Humana in Q4 2022, selling an estimated $383M.
- Marshall Wace's ten largest holdings make up 9.8% of its $44.5B portfolio in Q4 2022.
- Marshall Wace opened 652 new positions and closed 1,056 in Q4 2022.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $44.5B.
Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.